SCHEMBL26806537

SCHEMBL26806537

Cc1cccc(C)c1-c1cc(OC2CCCCC2)nc(NS(=O)(=O)c2cnn(C)c2)n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDK1 P06493 1/20 0.38
▸ CDK2 P24941 1/20 0.38
▸ GSK3B P49841 1/20 0.38
▸ TTK P33981 2/20 0.37
▸ MAPK8 P45983 2/20 0.37
▸ TSHR P16473 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ HTR1A P08908 6/20 0.35
▸ HTR7 P34969 6/20 0.35
▸ PTGS2 P35354 2/20 0.34
▸ PIK3CD O00329 1/20 0.34
▸ PIK3CB P42338 1/20 0.34
▸ MTOR P42345 1/20 0.34
▸ PIK3CG P48736 1/20 0.34
▸ PTGS1 P23219 4/20 0.34
▸ S1PR1 P21453 1/20 0.34
▸ DRD2 P14416 1/20 0.33
▸ HTR6 P50406 1/20 0.33
▸ JAK1 P23458 1/20 0.33
▸ NLRP3 Q96P20 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26815354 0.92 JAK1 (0.39) GSK3BTTKMAPK8TSHRSMN1; SMN2
SCHEMBL26806544 0.91 JAK1 (0.41) GSK3BTSHRSMN1; SMN2HTR1AHTR7
SCHEMBL26815402 0.90 PIM1 (0.45) TSHRSMN1; SMN2
SCHEMBL24309400 0.89 TSHR (0.36) GSK3BTSHRSMN1; SMN2HTR1AHTR7
SCHEMBL29566286 0.89 TSHR (0.36) GSK3BTSHRSMN1; SMN2HTR1AHTR7
SCHEMBL26806535 0.89 TSHR (0.35) TSHRSMN1; SMN2HTR1AHTR7PIK3CD
SCHEMBL26806515 0.88 TSHR (0.37) TSHRSMN1; SMN2HTR1AHTR7DRD2
SCHEMBL26809625 0.88 SCN8A (0.36) TSHRSMN1; SMN2HTR1AHTR7PIK3CD
SCHEMBL24309418 0.88 PIM1 (0.39) TSHRSMN1; SMN2HTR1AHTR7PIK3CD
SCHEMBL26806559 0.88 IRAK4 (0.37) TSHRSMN1; SMN2HTR1AHTR7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR VERTEX PHARMACEUTICALS, SAN DIEGO 2023-11-23 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230373935-A1 MODULATORS OF CYSTIC FIBROSIS TRANSMEMBRANE CONDUCTANCE REGULATOR CFTR, SCNN1G, SCNN1B CDK1 4718/4885CDK2 4552/4885GSK3B 3351/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback